Choosing the Right Angiotensin Converting Enzyme Inhibitors; Gender –Specific Approach

Abstract

This review article explores the importance of a masculinity- and feminine-specific approach in choosing the appropriate angiotensin-converting enzyme (ACE) inhibitors for patients with cardiovascular diseases. This review highlights the historical underrepresentation of women in clinical trials for cardiovascular medications, leading to a knowledge gap regarding the effectiveness and safety of these drugs in female patients. The article discusses the potential differences in treatment outcomes between men and women when it comes to ACE inhibitors and the gender-specific factors that can impact drug responses. The integration of bigender-specific data into clinical guidelines and decision-making processes can contribute to a more equitable and evidence-based approach to cardiovascular care. The article also references a report by the American College of Obstetricians and Gynecologists Force on Hypertension in Pregnancy, which emphasizes the importance of managing hypertension in pregnant women. By embracing a personalized medicine framework that accounts for gender-related differences, health-care professionals can optimize therapeutic interventions, minimize treatment disparities, and strive for improved cardiovascular health outcomes for all individuals. Overall, this review article provides insights into the potential mechanisms underlying sexuality-related differences in ACE inhibitor efficacy, safety, and adverse effects and discusses the implications of these findings in advancing personalized cardiovascular medicine.